abrdn Life Sciences Investors (HQL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, HQL scores 53 out of 100, equating to a D+ grade and the verdict label "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars, the Fundamental Cash Engine scores 11 of 20, reflecting a stated 0% ROIC and 0% FCF yield, which signals that the cash-generation engine is not currently contributing measurable return on capital. Whale 13F Flow scores 10 of 20 for institutional accumulation and options positioning, indicating limited evidence of strong institutional conviction. Insider Conviction scores 9 of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar, suggesting weak insider signaling. Macro Regime Fit scores 10 of 20, with a stated Beta of 1.0 and sector sensitivity that does not offer a clear tailwind. Forensic Balance Sheet scores 13 of 20, the strongest pillar, with an Altman Z of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the practical implication is that the rating frames this as a low-conviction profile: the balance sheet is the most supportive element, while cash returns, insider signaling, and institutional momentum are weak. Any upside case would need to rest on factors outside the cash engine, since the source data records no measurable ROIC or FCF yield to anchor valuation. The absence of earnings-based valuation metrics further limits how the current price can be benchmarked.

Per the recent news feed, five items relate to HQL, all with the impact label "MARKET WIRE" except one flagged as "CATALYST." Headlines reference the shares of beneficial interest estimates, a seasonal returns chart, a Seeking Alpha analysis stating the fund is currently overvalued, a report of the stock breaking above its 200-day moving average, and a MarketBeat report of a large increase in short interest. A separate item describes HQL rising 4.13% as shares reclaim ground toward resistance, tagged as a green-light catalyst. The overvaluation headline and the short-interest increase are the main risk-oriented items in the feed. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals recorded. Upstream and downstream dependencies cannot be mapped from the source data. Sector context is limited to the Financials / Investment Managers classification. Investors should watch for any future disclosure of counterparties or sector linkages, but no second-order ripples are documented in the provided sources.

• What are the reported revenue, net income, and free cash flow figures across recent periods, given that no financial statements were provided?
• What is the fund's underlying investment strategy and portfolio composition, and how does that drive its earnings and NAV-related economics?
• Why are TTM EPS and P/E unavailable, and how should the current $18.74 price be valued without them?
• What is the source and basis of the reported 0% ROIC and 0% FCF yield, and do they reflect the fund's actual economics?
• What is the current insider, 13F institutional, and Congressional trading activity underlying the low insider-conviction pillar score?